Good post Chris.

There is a part of me that wishes there would be a partnership prior to FDA approval if for nothing more to vindicate Al on what the perceived value of the product is.

On the other hand with my personal timeframe for this investment, I do not want to see the board make short-sighted decisions with the product. All of the other promising things in the pipeline (Technosphere, cancer line and the other drugs) success hinge on how MannKind does with Afrezza. Diluting the huge upside due to a cash flow nightmare brought on by the forced expenditures from the FDA will only limit the long term value of the company.

IMO big pharma knows what the real deal is. They also know the company is in a cash pinch for the duration of the approval process. They will play chicken as long as they can to get as much as they can from this deal. I read the financial posturing by Al in recent months as a signal that he is all in and it takes 2 play chicken. The only question I have is who blinks first.

I have already placed my bet on my choice.